<?xml version="1.0" encoding="UTF-8"?>
<ref id="B28">
 <label>28</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Han</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>Q</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Shi</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>Z</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial</article-title>. 
  <source>JAMA Oncol</source> (
  <year>2018</year>) 
  <volume>4</volume>:
  <page-range>1569–75</page-range>.  
  <pub-id pub-id-type="doi">10.1001/jamaoncol.2018.3039</pub-id>
 </mixed-citation>
</ref>
